The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...

At a median follow-up of 60.7 months, patients in the combination arm of enzalutamide + leuprolide had significantly superior 5-year metastasis free survival rates (87.3% versus 71.4%; HR: 0.42, 95% ...

Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...

Investing.com -- Novartis (SIX: NOVN) on Monday said that its cancer drug Pluvicto showed positive results in a late-stage ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...